Departments and research groups

Kong W, He L, Zhu J, Brück O, Porkka K, Heckman CA, Zhu S, Aittokallio T (2022)
An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia
Leukemia (in press)
DOI 10.1038/s41375-022-01662-6, PubMed 35945345

Berg J, Halvorsen AR, Bengtson MB, Lindberg M, Halvorsen B, Aukrust P, Helland Å, Ueland T (2022)
Circulating T Cell Activation and Exhaustion Markers Are Associated With Radiation Pneumonitis and Poor Survival in Non-Small-Cell Lung Cancer
Front Immunol, 13, 875152
DOI 10.3389/fimmu.2022.875152, PubMed 35911763

Skanland SS, Brown JR (2022)
PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
Haematologica (in press)
DOI 10.3324/haematol.2022.281266, PubMed 35899388

Venizelos A, Engebrethsen C, Deng W, Geisler J, Geisler S, Iversen GT, Aas T, Aase HS, Seyedzadeh M, Steinskog ES, Myklebost O, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Lønning PE, Knappskog S, Eikesdal HP (2022)
Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
Genome Med, 14 (1), 86
DOI 10.1186/s13073-022-01090-2, PubMed 35948919

Kong W, He L, Zhu J, Brück O, Porkka K, Heckman CA, Zhu S, Aittokallio T (2022)
An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia
Leukemia (in press)
DOI 10.1038/s41375-022-01662-6, PubMed 35945345

Ree AH, Mælandsmo GM, Flatmark K, Russnes HG, Gómez Castañeda M, Aas E (2022)
Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study
Acta Oncol, 1-8 (in press)
DOI 10.1080/0284186X.2022.2098053, PubMed 35943168